AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

STRATEC SE

Quarterly Report Nov 7, 2025

416_rns_2025-11-07_122621ad-829b-4574-b841-68daeea55da0.pdf

Quarterly Report

Open in Viewer

Opens in native device viewer

QUARTERLY STATEMENT 9M|2025

January 1 to September 30, 2025

STRATEC REPORTS DEFINITIVE RESULTS FOR FIRST NINE MONTHS OF 2025

  • Despite supply chain-induced interruption to production, consolidated sales at constant currency up 2.5% (nominal: +1.5%) to € 175.6 million in 9M/2025 (9M/2024: € 173.0 million)
  • Scale effects and higher earnings contributions from the realization of high-margin development sales are expected to drive significantly more dynamic earnings momentum in the fourth quarter of 2025
  • Ongoing great momentum and strong demand for system solution development cooperations; new partnerships initiated
  • 2025 guidance: sales at constant currency expected at around previous year's level with adjusted EBIT margin at lower end of forecast corridor of 10.0% to 12.0%

Key figures1

€ 000s 9M 2025 9M 20242 Change Q3 2025 Q3 20242 Change
Sales 175,588 172,958 +1.5%
(cc: +2.5%)
56,998 60,267 -5.4%
(cc: -3.4%)
Adjusted EBITDA 24,235 26,623 -9.0% 8,165 9,197 -11.2%
Adjusted EBITDA margin (%) 13.8 15.4 -160 bps 14.3 15.3 -100 bps
Adjusted EBIT 12,824 15,149 -15.3% 4,337 5,269 -17.7%
Adjusted EBIT margin (%) 7.3 8.8 -150 bps 7.6 8.7 -110 bps
Adjusted consolidated net income 7,104 8,434 -15.8% 2,126 2,831 -24.9%
Adjusted earnings per share (€) 0.58 0.69 -15.9% 0.17 0.23 -26.1%
Earnings per share (€) 0.34 0.39 -12.8% 0.13 0.06 +116.7%

bps = basis points cc = constant currency

Restated pursuant to IAS 8.

To facilitate comparison, figures for 2025 have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and restructuring expenses). The figures for 2024 have additionally been adjusted to exclude one-off personnel expenses of € 1.7 million in connection with the departure of a member of the Board of Management.

BUSINESS PERFORMANCE

STRATEC increased its consolidated sales year-on-year by 2.5% on a constant-currency basis (nominal: +1.5%) to € 175.6 million in the first nine months of 2025 (9M/2024: € 173.0 million). Systems sales at constant currency virtually matched the previous year's level. Alongside start-up curves for new product launches remaining flatter than usual, the third quarter also brought supply chain interruptions in connection with trade policy tensions and thus delivery backlogs with some system lines. By contrast, the stabilization in demand for system lines which had seen disruptions in the wake of the COVID-19 pandemic continued apace. Constantcurrency sales with Service Parts and Consumables fell slightly short of the previous year's high figure. In the third quarter of 2025, this division felt the effects of volatile order behavior and logistics optimization measures taken by customers to account for changeable global tariff restrictions. Conversely, sales with Development and Services showed double-digit percentage growth, benefiting from a high volume of development activities and numerous customer projects currently underway.

Adjusted EBIT amounted to € 12.8 million in the first nine months of 2025 (9M/2024: € 15.1 million). Compared with the previous year, the adjusted EBIT margin thus fell by 150 basis points from 8.8% to 7.3%. This was particularly due to product mix effects within the Systems operating division, as well as to a temporary dip in the share of high-margin Service Parts and Consumables in the third quarter of 2025. The margin performance was additionally held back by negative exchange rate effects.

Adjusted consolidated net income stood at € 7.1 million in the first nine months of 2025, compared with € 8.4 million in the previous year. Here, STRATEC witnessed a year-on-year improvement in its net financial expenses and an increase in its adjusted tax rate. Adjusted earnings per share (basic) amounted to € 0.58 (9M/2024: € 0.69).

Reconciliation of adjusted EBITDA, EBIT, and consolidated net income

The key earnings figures for the first nine months of 2025 have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and restructuring expenses). A reconciliation of the adjusted results with the unadjusted key earnings figures is presented below:

Reconciliation of adjusted EBITDA (€ 000s)

9M/2025 9M/20241
Adjusted EBITDA 24,235 26,623
Adjustments:
Other2 -1,677 -2,052
EBITDA 22,558 24,571

1 Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report.

Reconciliation of adjusted EBIT (€ 000s)

9M/2025 9M/20241
Adjusted EBIT 12,824 15,149
Adjustments:
PPA amortization -2,309 -2,772
Other2 -1,677 -2,052
EBIT 8,838 10,325

1 Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report.

Reconciliation of adjusted consolidated net income (€ 000s)

9M/2025 9M/20241
Adjusted consolidated net income 7,104 8,434
Adjusted earnings per share in €
(basic)
0.58 0.69
Adjustments:
PPA amortization -2,309 -2,772
Other2 -1,677 -2,052
Taxes 985 1,156
Consolidated net income 4,103 4,766
Earnings per share in € (basic) 0.34 0.39

1 Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report.

Including one-off advisory expenses, fees, and restructuring expenses

2 Including one-off advisory expenses, fees, and restructuring expenses

2 Including one-off advisory expenses, fees, and restructuring expenses

FINANCIAL GUIDANCE

As already communicated in the announcement published on October 30, 2025, STRATEC expects to witness temporary interruptions to the supply of input materials for some system lines in the fourth quarter of 2025. In particular, in connection with trade policy tensions supply chain interruptions have arisen for a specific type of magnet with impurities relating to export-restricted rare earths (share of rare earths in affected production batch: 0.1%). Against this backdrop, delivery backlogs already arose for system deliveries in the third quarter of 2025. STRATEC does not expect to receive sufficient quantities of input materials to make up for these delivery backlogs or for the production volumes originally planned for the fourth quarter of 2025. Furthermore, global tariff conflicts are leading to higher fluctuations in customers' order behavior and to associated logistics optimization measures. These particularly affect the Service Parts and Consumables division. In view of these factors, on October 30, 2025 the Board of Management decided to adjust its sales guidance for the 2025 financial year. STRATEC now expects its consolidated sales at constant currency to approximately match the previous year's figure. Despite the lower sales base hereby forecast and negative currency items, STRATEC confirmed the lower end of the forecast corridor of around 10.0% to 12.0% for its adjusted EBIT margin. The expected intra-year rise in profitability in the fourth quarter of 2025 is attributable to benefits of scale, efficiency measures, and higher earnings contributions from the realization of high-margin development sales.

Based on updated planning, STRATEC assumes that its investments in property, plant and equipment and intangible assets in the 2025 financial year will fall slightly short of the originally forecast range of a total of 8.0% to 10.0% of sales (2024: 7.1%).

PROJECTS AND OTHER DEVELOPMENTS

Together with its partners, in the third quarter of 2025 STRATEC once again made further scheduled progress with numerous development projects and paved the way for additional cooperation agreements. The increasing willingness shown by customers in recent months to reach decisions concerning cooperations in the Systems Development business continued. Among other aspects, STRATEC has observed growing demand for lifecycle transfers. Furthermore, customers are increasingly looking for partners who are able to assume full responsibility for design, production, and delivery for the entire product lifecycle. The background to this development involves reorganization measures and M&A activities at customers, as well as their strategic focus on products already established in the market. These factors are supplemented by changed market conditions and growing requirements in terms of materials procurement. Against this backdrop, STRATEC recently initiated a partnership for a well-established high-throughput product in the field of molecular diagnostics.

The third quarter of 2025 also saw the market launch of the P780, a next-generation analyzer system offered under the Diatron brand in the field of clinical chemistry. To address a wide range of target customers, the P780 was developed for medium to large laboratories, offering an innovative and scalable solution characterized by great reliability.

DEVELOPMENT IN PERSONNEL

Including personnel hired from temporary employment agencies and trainees, the STRATEC Group had a total of 1,420 employees as of September 30, 2025 (previous year: 1,462 employees). This corresponds to a reduction of 2.9% compared with the previous year's reporting date and is to be viewed in connection with the continuation in 2025 of the measures taken to enhance efficiency and improve earnings.

CONSOLIDATED BALANCE SHEET

as of September 30, 2025

Assets

€ 000s 09.30.2025 12.31.2024
Non-current assets
Goodwill 49,597 50,975
Other intangible assets 64,447 62,889
Right-of-use assets 12,914 15,180
Property, plant and equipment 64,771 65,065
Non-current financial assets 4,086 3,472
Non-current other receivables and assets 343 0
Non-current contract assets 23,170 20,859
Deferred taxes 3,922 3,116
223,250 221,556
Current assets
Inventories 126,389 121,818
Trade receivables 41,947 41,578
Current financial assets 1,617 1,563
Current other receivables and assets 6,898 7,951
Current contract assets 7,545 1,209
Income tax receivables 1,194 2,219
Cash 22,396 47,164
207,986 223,502
Total assets 431,236 445,058

Shareholders' equity and debt

€ 000s 09.30.2025 12.31.2024
Shareholders' equity
Share capital 12,158 12,158
Capital reserve 37,723 37,131
Revenue reserves 194,076 197,267
Treasury stock -35 -35
Other equity -3,844 -3,988
240,078 242,533
Non-current debt
Non-current financial liabilities 116,952 88,695
Current other liabilities 1,330 1,201
Non-current contract liabilities 2,112 343
Provisions for pensions 5,117 5,338
Provisions 156 190
Deferred taxes 15,908 16,412
141,575 112,179
Current debt
Current financial liabilities 15,290 45,565
Trade payables 14,418 18,447
Current other liabilities 9,351 10,369
Current contract liabilities 7,216 7,235
Provisions 622 760
Income tax liabilities 2,686 7,970
49,583 90,346
Total shareholders' equity and debt 431,236 445,058

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the period from January 1 to September 30, 2025

€ 000s 01.01. – 09.30.2025 01.01. – 09.30.2024
Retrospectively
adjusted1
Sales 175,588 172,958
Cost of sales -130,331 -125,672
Gross profit 45,257 47,286
Research and development expenses -7,012 -8,123
Sales-related expenses -8,973 -9,992
General administration expenses -18,992 -18,597
Income / Expenses from impairment of financial assets
and contract assets
-614 -11
Other operating expenses -4,752 -4,038
Other operating income 3,924 3,800
Earnings before interest and taxes (EBIT) 8,838 10,325
Financial income 154 275
Financial expenses -3,140 -4,486
Other financial result -179 88
Net financial result -3,165 -4,123
Earnings before taxes (EBT) 5,673 6,202
Taxes on income -1,570 -1,436
Consolidated net income 4,103 4,766
Items that may be subsequently reclassified to profit or loss:
Currency translation differences from translation of foreign operations 142 -4,104
Other comprehensive income (OCI) 142 -4,104
Comprehensive income 4,245 662
Basic earnings per share in € 0.34 0.39
No. of shares used as basis (undiluted) 12,155,942 12,155,942
Diluted earnings per share in € 0.34 0.39
No. of shares used as basis (diluted) 12,155,942 12,157,875

1 Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the period from July 1 to September 30, 2025

€ 000s 01.01. – 09.30.2025 01.01. – 09.30.2024
Retrospectively
adjusted1
Sales 56,998 60,267
Cost of sales -43,696 -43,527
Gross profit 13,302 16,740
Research and development expenses -1,587 -2,563
Sales-related expenses -2,466 -3,140
General administration expenses -6,004 -7,337
Income / Expenses from impairment of financial assets
and contract assets
-196 -20
Other operating expenses -622 -1,461
Other operating income 1,092 217
Earnings before interest and taxes (EBIT) 3,519 2,436
Financial income 33 5
Financial expenses -1,056 -1,483
Other financial result -117 89
Net financial result -1,140 -1,389
Earnings before taxes (EBT) 2,379 1,047
Taxes on income -878 -327
Consolidated net income 1,501 720
Items that may be subsequently reclassified to profit or loss:
Currency translation differences from translation of foreign operations 1,690 -434
Other comprehensive income (OCI) 1,690 -434
Comprehensive income 3,191 286
Basic earnings per share in € 0.13 0.06
No. of shares used as basis (undiluted) 12,155,942 12,155,942
Diluted earnings per share in € 0.13 0.06
No. of shares used as basis (diluted) 12,155,942 12,157,686

1 Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report.

CONSOLIDATED CASH FLOW STATEMENT

for the period from January 1 to September 30, 2025

€ 000s 01.01. – 09.30.2025 01.01. – 09.30.2024
Retrospectively
adjusted1
I. Operations
Consolidated net income (after taxes) 4,103 4,766
Depreciation and amortization 13,720 14,246
Current income tax expenses 3,023 1,513
Income taxes paid less income taxes received -7,253 -171
Financial income -154 -275
Financial expenses 3,140 4,486
Interest paid -3,420 -4,542
Interest received 224 275
Other non-cash expenses 4,227 1,732
Other non-cash income -2,046 -1,195
Change in net pension provisions through profit or loss -252 -23
Change in deferred taxes through profit or loss -1,453 -77
Profit (-) / loss (+) on disposals of non-current assets 13 74
Increase (-) / decrease (+) in inventories, trade receivables and other assets -11,685 4,418
Increase (+) / decrease (-) in trade payables and other liabilities -3,622 203
Cash flow from operating activities -1,435 25,430
II. Investments
Incoming payments from disposals of non-current assets
• Property, plant and equipment
0 9
Outgoing payments for investments in non-current assets
• Intangible assets
-5,671 -6,344
• Property, plant and equipment
• Financial assets
-7,124
-580
-5,997
-100
Cash flow from investing activities -13,375 -12,432
III. Financing
Incoming funds from taking up of financial liabilities 42,000 12,000
Outgoing payments for repayment of financial liabilities -41,109 -16,388
Outgoing payments for repayment of lease liabilities -2,568 -2,407
Dividend payments -7,294 -6,687
Cash flow from financing activities -8,971 -13,482
IV. Cash-effective change in cash (net balance I – III) -23,781 -484
Cash at start of period 47,164 33,532
Impact of exchange rate movements -987 60
Cash at end of period 22,396 33,108

1 Restated pursuant to IAS 8. Further details can be found in the 2024 Annual Report.

FINANCIAL CALENDAR

Subject to amendment.

Quarterly statements and half-year financial reports are neither audited nor subject to an audit review by the group auditor.

ABOUT STRATEC

STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life siences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For its analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.

IMPRINT AND CONTACT

Published by

STRATEC SE Gewerbestr. 37 75217 Birkenfeld Germany

Phone: +49 7082 7916-0

[email protected] www.stratec.com

Head of Investor Relations, Sustainability & Corporate Communications

Jan Keppeler Phone: +49 7082 7916- 6515 [email protected]

Notice

Forward-looking statements involve risks: This quarterly statement contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This quarterly statement contains various disclosures that from an economic point of view are not required by the relevant accounting standards. These disclosures should be regarded as a supplement, rather than a substitute for the IFRS disclosures.

Apparent discrepancies may arise throughout this quarterly statement on account of mathematical rounding up or down in the course of addition.

This quarterly statement is available in both German and English. Both versions can be downloaded from the company's website at www. stratec.com. In the event of any discrepancies between the two, the German report is the definitive version.

Talk to a Data Expert

Have a question? We'll get back to you promptly.